However, it may be asked whether IDO is an effective target, since phase III ECHO301 trial of epacadostat, another inhibitor of IDO, with pembrolizumab for melanoma as a combination therapy failed, missing the first primary endpoint of improving PFS vs. pembrolizumab alone (198). Here, IDO1 is linked to melanoma.